vs
Side-by-side financial comparison of Xiao-I Corp (AIXI) and Neuphoria Therapeutics Inc. (NEUP). Click either name above to swap in a different company.
Neuphoria Therapeutics Inc. is the larger business by last-quarter revenue ($15.0M vs $11.5M, roughly 1.3× Xiao-I Corp). Neuphoria Therapeutics Inc. runs the higher net margin — 75.1% vs -263.9%, a 339.0% gap on every dollar of revenue.
Xiao-i is a Chinese cognitive artificial intelligence enterprise founded in 2001.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
AIXI vs NEUP — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $15.0M |
| Net Profit | $-30.4M | $11.3M |
| Gross Margin | 58.1% | — |
| Operating Margin | -254.9% | 79.8% |
| Net Margin | -263.9% | 75.1% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $6.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $11.5M | — | ||
| Q1 25 | — | $15.0M | ||
| Q2 24 | $33.0M | — | ||
| Q2 23 | $26.5M | — |
| Q2 25 | $-30.4M | — | ||
| Q1 25 | — | $11.3M | ||
| Q2 24 | $-15.5M | — | ||
| Q2 23 | $-18.8M | — |
| Q2 25 | 58.1% | — | ||
| Q1 25 | — | — | ||
| Q2 24 | 64.5% | — | ||
| Q2 23 | 77.3% | — |
| Q2 25 | -254.9% | — | ||
| Q1 25 | — | 79.8% | ||
| Q2 24 | -45.0% | — | ||
| Q2 23 | -51.5% | — |
| Q2 25 | -263.9% | — | ||
| Q1 25 | — | 75.1% | ||
| Q2 24 | -47.2% | — | ||
| Q2 23 | -70.9% | — |
| Q2 25 | — | — | ||
| Q1 25 | — | $6.55 | ||
| Q2 24 | $-0.64 | — | ||
| Q2 23 | $-0.80 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $17.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $26.0M |
| Total Assets | $82.4M | $30.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $5.0M | — | ||
| Q1 25 | — | $17.0M | ||
| Q2 24 | $1.8M | — | ||
| Q2 23 | $4.7M | — |
| Q2 25 | — | — | ||
| Q1 25 | — | $26.0M | ||
| Q2 24 | — | — | ||
| Q2 23 | $525.1K | — |
| Q2 25 | $82.4M | — | ||
| Q1 25 | — | $30.7M | ||
| Q2 24 | $87.6M | — | ||
| Q2 23 | $51.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.3M | $11.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $-2.3M | — | ||
| Q1 25 | — | $11.5M | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q2 25 | — | — | ||
| Q1 25 | — | 1.02× | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
